3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
7
INDUSTRY
4
OTHER_GOV
1
NIH
1
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Esophageal Squamous Cell Carcinoma
1
Interventions
Bevacizumab
5
Capecitabine
3
toripalimab
2
olaparib
2
durvalumab
2
darolutamide
2
atezolizumab
2
apatinib
2
anlotinib
2
Standard of Care
2
Radiotherapy
2
Radiosurgery
2
Oxaliplatin
2
Leucovorin
2
Laparoscopy
2
Immunotherapy
2
Fluorouracil
2
Drug Therapy
2
130-nm albumin-bound paclitaxel
2
trametinib
1
spartalizumab
1
pyrotinib
1
pomalidomide
1
palbociclib
1
nilotinib
1
ledipasvir, sofosbuvir drug combination
1
ledipasvir
1
irinotecan sucrosofate
1
hetrombopag
1
glasdegib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER_GOV
×
Platinum Compounds
×
90 days
×
Clear all
NCT07629817
2026-06-05
HCHTOG2603
Henan Cancer Hospital
Phase 3
Not yet recruiting
1,044 enrolled